Letter to the Editor: “Cost-effectiveness and budget impact analysis of the implementation of differentiated service delivery models for HIV treatment in Mozambique: a modelling study”: Resource reductions are not equal to cost savings

IF 4.6 1区 医学 Q2 IMMUNOLOGY
Sydney Rosen, Nkgomeleng Lekodeba, Linda Sande, Brooke Nichols
{"title":"Letter to the Editor: “Cost-effectiveness and budget impact analysis of the implementation of differentiated service delivery models for HIV treatment in Mozambique: a modelling study”: Resource reductions are not equal to cost savings","authors":"Sydney Rosen,&nbsp;Nkgomeleng Lekodeba,&nbsp;Linda Sande,&nbsp;Brooke Nichols","doi":"10.1002/jia2.26367","DOIUrl":null,"url":null,"abstract":"<p>For the past decade, differentiated service delivery has been a major focus of national HIV treatment programmes in sub-Saharan Africa [<span>1-3</span>]. While its main objective has been to make antiretroviral therapy (ART) provision more client-centred, it has also been seen as a way to increase the efficiency of ART delivery, largely by lowering the “intensity” of care by allowing less frequent clinic visits, longer medication dispensing intervals, out-of-facility service locations, and, in some cases, task shifting to lower-paid or less skilled staff cadres [<span>4, 5</span>]. The few published studies of the costs of differentiated service delivery (DSD) models have had conflicting results, with the simplest models of care, such as facility-based 6-month dispensing of medications, appearing to cost less than conventional care per client served and other models, such as adherence clubs, potentially costing more [<span>6, 7</span>].</p><p>Given the variation in cost results to date, we read with interest the paper by Uetela et al. [<span>8</span>] reporting their cost-effectiveness and budget impact analysis of DSD models for HIV treatment in Mozambique. Studies of this type turn out to be far more challenging to conduct than they first appear, because of the difficulty of defining a comparison population, obtaining complete individual-level data on resource utilization, observing actual resource utilization for health system interactions that often occur outside fixed healthcare facilities, accounting for participants who switch models during the study observation period, and incorporating individual facility idiosyncrasies in model implementation. We therefore congratulate the authors for their effort in pulling together all the disparate types of data needed to make these estimates.</p><p>We do, however, have one major concern about this paper's conclusions that we believe should be called to readers’ attention. The paper states that “the implementation of these models will result in savings of approximately US$14 million to the health system between 2022 and 2024.” It is critical to note that, as far as we can tell, none of these “savings” is in fact a cash or budgetary saving to the health system. The “savings” reported are generated primarily by a reduction in the use of healthcare provider time required by the DSD models. This is time that facility managers can reallocate to other purposes, and it may allow them to see more clients or provide higher-quality care to existing clients, but it does not represent money saved, unless absolute numbers of healthcare staff are reduced, for example by laying off nurses or pharmacy technicians. We have never encountered a healthcare system in this region that is either able or willing to reduce its total complement of healthcare workers in response to the advent of DSD models. No mechanism or pathway exists for DSD models to “save money.” They do, without doubt, save resources (e.g. staff time, facility space), and it is desirable and likely that these resources can be used to produce more health for other clinic clients. DSD will not, however, reduce the Ministry of Health's ART budget. Policymakers should take this into account in considering the net benefits of DSD.</p><p>The authors report no competing interests.</p><p>SR: Original draft of the manuscript. All authors contributed to the overall message of the manuscript, revised the draft, and reviewed and approved the final manuscript.</p><p>Funding for the study was provided by the Bill &amp; Melinda Gates Foundation through INV-037138 to the Wits Health Consortium and INV-031690 to Boston University. The funders had no role in study design, data collection, analysis, or interpretation of data or in the writing of this manuscript.</p>","PeriodicalId":201,"journal":{"name":"Journal of the International AIDS Society","volume":"27 10","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jia2.26367","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the International AIDS Society","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jia2.26367","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

For the past decade, differentiated service delivery has been a major focus of national HIV treatment programmes in sub-Saharan Africa [1-3]. While its main objective has been to make antiretroviral therapy (ART) provision more client-centred, it has also been seen as a way to increase the efficiency of ART delivery, largely by lowering the “intensity” of care by allowing less frequent clinic visits, longer medication dispensing intervals, out-of-facility service locations, and, in some cases, task shifting to lower-paid or less skilled staff cadres [4, 5]. The few published studies of the costs of differentiated service delivery (DSD) models have had conflicting results, with the simplest models of care, such as facility-based 6-month dispensing of medications, appearing to cost less than conventional care per client served and other models, such as adherence clubs, potentially costing more [6, 7].

Given the variation in cost results to date, we read with interest the paper by Uetela et al. [8] reporting their cost-effectiveness and budget impact analysis of DSD models for HIV treatment in Mozambique. Studies of this type turn out to be far more challenging to conduct than they first appear, because of the difficulty of defining a comparison population, obtaining complete individual-level data on resource utilization, observing actual resource utilization for health system interactions that often occur outside fixed healthcare facilities, accounting for participants who switch models during the study observation period, and incorporating individual facility idiosyncrasies in model implementation. We therefore congratulate the authors for their effort in pulling together all the disparate types of data needed to make these estimates.

We do, however, have one major concern about this paper's conclusions that we believe should be called to readers’ attention. The paper states that “the implementation of these models will result in savings of approximately US$14 million to the health system between 2022 and 2024.” It is critical to note that, as far as we can tell, none of these “savings” is in fact a cash or budgetary saving to the health system. The “savings” reported are generated primarily by a reduction in the use of healthcare provider time required by the DSD models. This is time that facility managers can reallocate to other purposes, and it may allow them to see more clients or provide higher-quality care to existing clients, but it does not represent money saved, unless absolute numbers of healthcare staff are reduced, for example by laying off nurses or pharmacy technicians. We have never encountered a healthcare system in this region that is either able or willing to reduce its total complement of healthcare workers in response to the advent of DSD models. No mechanism or pathway exists for DSD models to “save money.” They do, without doubt, save resources (e.g. staff time, facility space), and it is desirable and likely that these resources can be used to produce more health for other clinic clients. DSD will not, however, reduce the Ministry of Health's ART budget. Policymakers should take this into account in considering the net benefits of DSD.

The authors report no competing interests.

SR: Original draft of the manuscript. All authors contributed to the overall message of the manuscript, revised the draft, and reviewed and approved the final manuscript.

Funding for the study was provided by the Bill & Melinda Gates Foundation through INV-037138 to the Wits Health Consortium and INV-031690 to Boston University. The funders had no role in study design, data collection, analysis, or interpretation of data or in the writing of this manuscript.

致编辑的信:"在莫桑比克实施艾滋病毒治疗差异化服务提供模式的成本效益和预算影响分析:一项模拟研究":资源减少不等于成本节约
过去十年来,提供有区别的服务一直是撒哈拉以南非洲国家艾滋病毒治疗计划的主要重点[1-3]。虽然其主要目的是使抗逆转录病毒疗法(ART)的提供更加以客户为中心,但它也被视为提高抗逆转录病毒疗法提供效率的一种方法,主要是通过减少出诊次数、延长配药间隔、在机构外提供服务,以及在某些情况下将任务转移给薪酬较低或技能较差的工作人员来降低护理的 "强度"[4, 5]。已发表的为数不多的关于差异化服务提供(DSD)模式成本的研究结果相互矛盾,最简单的护理模式(如基于设施的 6 个月配药)似乎比传统护理模式每服务一位客户的成本低,而其他模式(如依从性俱乐部)则可能成本更高[6, 7]。鉴于迄今为止成本结果的差异,我们饶有兴趣地阅读了 Uetela 等人[8]的论文,该论文报告了他们对莫桑比克 HIV 治疗的差异化服务提供模式的成本效益和预算影响分析。由于难以确定对比人群,难以获得完整的个人层面资源利用数据,难以观察经常发生在固定医疗机构之外的医疗系统互动的实际资源利用情况,难以考虑在研究观察期间转换模式的参与者,以及难以在模式实施过程中考虑个别医疗机构的特殊性,因此开展此类研究的难度远比最初看起来要大得多。因此,我们祝贺作者努力汇集了进行这些估算所需的所有不同类型的数据。不过,我们对本文的结论有一个重大疑虑,我们认为应该提请读者注意。本文指出,"这些模式的实施将在 2022 年至 2024 年间为卫生系统节省约 1400 万美元"。必须指出的是,就我们所知,这些 "节省 "实际上都不是为卫生系统节省现金或预算。所报告的 "节省 "主要是由于减少了医疗服务提供者使用数据集定义模型所需的时间。医疗机构的管理人员可以将这些时间重新分配到其他用途上,这样他们就可以为更多的病人看病,或为现有的病人提供更高质量的医疗服务,但这并不代表节省了资金,除非减少了医护人员的绝对数量,例如裁减护士或药房技术人员。在本地区,我们从未遇到过一个医疗保健系统能够或愿意减少医护人员的总编制,以应对数据集定义模式的出现。目前还没有任何机制或途径能让数据集定义模式 "省钱"。毫无疑问,它们确实节省了资源(如工作人员的时间、设施空间),而且这些资源可以用于为其他诊所的客户提供更多的健康服务,这是可取的,也是可能的。然而,DSD 不会减少卫生部的抗逆转录病毒疗法预算。作者报告没有利益冲突。所有作者都参与了稿件的整体构思,修改了稿件,审阅并批准了最终稿件。研究经费由比尔-盖茨基金会(Bill & Melinda Gates Foundation)通过 INV-037138 向 Wits Health Consortium 提供,并通过 INV-031690 向波士顿大学提供。资助方未参与研究设计、数据收集、分析或数据解释,也未参与本手稿的撰写。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of the International AIDS Society
Journal of the International AIDS Society IMMUNOLOGY-INFECTIOUS DISEASES
CiteScore
8.60
自引率
10.00%
发文量
186
审稿时长
>12 weeks
期刊介绍: The Journal of the International AIDS Society (JIAS) is a peer-reviewed and Open Access journal for the generation and dissemination of evidence from a wide range of disciplines: basic and biomedical sciences; behavioural sciences; epidemiology; clinical sciences; health economics and health policy; operations research and implementation sciences; and social sciences and humanities. Submission of HIV research carried out in low- and middle-income countries is strongly encouraged.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信